FDA Shortage Notification Mandate May Not Extend To Biologics
Executive Summary
The agency has the option to issue regulations requiring biologics manufacturers to notify FDA of emerging production problems, but so far it’s only “something that we’re thinking about.”
You may also be interested in...
Biosimilar Legislation Could Upend Interchangeability Rather Than Prevent Product Hopping
Rep. Kurt Schrader’s bill could allow a first interchangeable product to block all strengths with its one-year exclusivity, rather than just the one developed.
Biosimilar Legislation Could Upend Interchangeability Rather Than Prevent Product Hopping
Rep. Kurt Schrader’s bill could allow a first interchangeable product to block all strengths with its one-year exclusivity, rather than just the one developed.
Drug Shortage Prevention May Fall To Payers As FDA Rolls Out New Reg
Even as agency touts its progress and expands its powers, it acknowledges the limits of notification.